As previously discussed, combinations of different immunotherapy targets or immunotherapy with chemotherapy/radiotherapy/targeted therapy improve the response rate of MSS CRC to PD-L1 inhibitors (17–21). The gene discussed is CD274; the disease is colorectal carcinoma.